2020
DOI: 10.1016/j.dsx.2020.09.019
|View full text |Cite
|
Sign up to set email alerts
|

The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
47
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(47 citation statements)
references
References 25 publications
0
47
0
Order By: Relevance
“… 19 Only one study used proper allocation concealment to ensure that the trial investigators and participants were masked to treatment allocation. 22 The funnel plot and Egger’s test ( p = 0.277) suggested that the studies had no significant publication bias ( Figure 3 ). The overall risk of bias across all included studies was low.…”
Section: Resultsmentioning
confidence: 97%
See 2 more Smart Citations
“… 19 Only one study used proper allocation concealment to ensure that the trial investigators and participants were masked to treatment allocation. 22 The funnel plot and Egger’s test ( p = 0.277) suggested that the studies had no significant publication bias ( Figure 3 ). The overall risk of bias across all included studies was low.…”
Section: Resultsmentioning
confidence: 97%
“… 19–21 One study used a 5×4 grid in the sole of the foot. 22 All included studies used BTX-A for the injections. The dosage range of BTX-A was between 50 and 150 units in each foot.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Another prospective trial looked at the efficacy of BTX-A for diabetic polyneuropathy, which randomized 141 patients aged 40 to 70 years into three groups: the first group was injected with 150U BTX-A on one side of the foot and 0.9% saline on the other side; the second group was injected with 150U BTX-A in both feet; the third group was injected with 0.9% physiological saline, using VAS and NPS for comparison. The results showed a significant improvement in VAS and NPS (except dull and cold sensation) scores in the BTX-A group compared with the saline group, indicating that intradermal injection of BTX-A was effective in treating good diabetic polyneuropathy (Taheri et al, 2020). All of the above results demonstrate that BTX-A effectively improves neuropathic pain in diabetic patients, although different results were shown on NPS, which may be related to sample size and BTX-A dose.…”
Section: Diabe C Neuropathy Painmentioning
confidence: 84%
“…There was a significant improvement in VAS in the BTX-A group versus the placebo group, while VAS scores did not differ significantly between the BTX-A groups (Taheri et al, 2020) revealed that after single and continuous injections of BTX-A, the severity of pain in patients was significantly reduced, the efficiency of pain relief was 100% in both cases, and there was no significant difference in the mean duration of pain relief. No significant adverse effects were seen in either case, suggesting that repeated injections of BTX-A are safe and effective (Gorimanipalli et al, 2019).…”
Section: Trigeminal Neuralgiamentioning
confidence: 84%